Chromadex Corp.
(NASDAQ : CDXC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Process Industries » Chemicals Specialty
symbolcompany%chnglast%shortavg$volume
LINLinde Plc 0.90%284.730.0%$506.24m
APDAir Products & Chemicals, Inc. 0.40%284.231.5%$281.64m
DOWDow, Inc. 0.02%63.202.4%$259.64m
ECLEcolab, Inc. 1.65%219.541.6%$228.82m
DQDaqo New Energy Corp. 4.55%69.230.2%$189.62m
LYBLyondellBasell Industries NV 1.14%104.172.8%$174.16m
ALBAlbemarle Corp. 0.87%147.443.4%$153.99m
GEVOGevo, Inc. -4.98%8.200.9%$132.58m
AVTRAvantor, Inc. 0.60%31.710.0%$113.87m
REGIRenewable Energy Group, Inc. -1.79%63.7821.8%$102.55m
AMRSAmyris, Inc. 3.43%16.594.5%$85.29m
AMTXAemetis, Inc. -0.34%26.100.7%$72.91m
LTHMLivent Corp. -0.58%17.080.0%$42.68m
ASHAshland Global Holdings, Inc. 0.90%88.793.3%$34.14m
CHXChampionX Corp. -1.59%20.480.0%$31.81m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.